|
⚲
|
| Keyboard |
| NQ HCIF General Partner LP
✚
|
|
|---|---|
| CIK # | 0001598327 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-NT | [0001598327] | |
| 3 | [0001598327] | |
| 4 | [0001598327] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| NQ HCIF General Partner LP | |
| NovaQuest Pharma Opportunities Fund III LP | |
| NQ HCIF GP Ltd | |
| Revance Therapeutics Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Revance Therapeutics Inc RVNC
Stock Option (Right to Buy) · derivative
|
2015-05-07 | Other | 8,000 | $0.00 | |
|
Revance Therapeutics Inc RVNC
Stock Option (Right to Buy) · derivative
|
2015-05-07 | Other | 8,000 | $0.00 | |
|
Revance Therapeutics Inc RVNC
Stock Option (Right to Buy) · derivative
|
2014-04-08 | Other | 8,000 | $0.00 | |
|
Revance Therapeutics Inc RVNC
Stock Option (Right to Buy) · derivative
|
2014-04-08 | Other | 8,000 | $0.00 | |
|
Revance Therapeutics Inc RVNC
Series E-5 Convertible Preferred Stock · derivative
|
2014-02-11 | Conversion | 500,039 | ||
|
Revance Therapeutics Inc RVNC
Common Stock
|
2014-02-11 | Conversion | 2,039,382 | ||
|
Revance Therapeutics Inc RVNC
Warrant to Purchase Common Stock · derivative
|
2014-02-11 | Option exercise | 398,717 | ||
|
Revance Therapeutics Inc RVNC
Series E-4 Convertible Preferred Stock · derivative
|
2014-02-11 | Conversion | 1,539,343 | ||
|
Revance Therapeutics Inc RVNC
Common Stock
|
2014-02-11 | Option exercise | 398,717 | ||
|
Revance Therapeutics Inc RVNC
Common Stock
|
2014-02-11 | Conversion | 658,551 | ||
|
Revance Therapeutics Inc RVNC
Convertible Promissory Notes · derivative
|
2014-02-11 | Conversion | 658,551 |